Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech giant Biogen Idec
So what: In a clinical trial, BG-12 was shown to be highly effective for the very first time, which certainly boosts Biogen's position in the attractive, yet increasingly competitive, market for oral MS drugs. In fact, based on the initial data, BG-12 appears to be more effective than Teva Pharmaceutical's
Now what: Don't let today's big rally keep you from looking into the stock. Lost in the BG-12 hubbub were Biogen's first-quarter profit growth of 35%, which easily topped Wall Street estimates, and the reaffirmation of its strong full-year outlook. When you add BG-12's blockbuster potential to an already solidly performing multiple sclerosis portfolio, Biogen seems like a relatively solid biotech bet.
Interested in more info on Biogen? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Teva is a Motley Fool Global Gains pick, and the Fool owns shares of it. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Will 2018 Be Biogen Inc.'s Best Year Yet?
You probably don't want to bet the farm on it.
5 Biotech Buyout Candidates for 2018
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Biogen Inc. Buys Its Way Out of Competition
The big biotech gains rights to a potential Tecfidera competitor from Alkermes.